Polyplus-transfection Enters Reagent Deal with Roche Glycart

Jan 24, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.

As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.

Based in Strasbourg, France, Polyplus-transfection is a privately held biotech firm that develops solutions for the in vivo, in vitro, an ex vivo delivery of nucleic acids for research, bioproduction, and therapeutic applications.

Roche Glycart is a Swiss biotechnology firm owed by Roche.

Terms of the deal were not disclosed.

Filed under

licensing agreement

Polyplus-transfection

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.